| Dr Mohamed Abdul Karim Sekkarie, MD | |
|
4235 Secor Rd, Toledo, OH 43623-4231 | |
| (419) 479-5529 | |
| Not Available |
| Full Name | Dr Mohamed Abdul Karim Sekkarie |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 43 Years |
| Location | 4235 Secor Rd, Toledo, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841206695 | NPI | - | NPPES |
| 0073236000 | Medicaid | WV | |
| 010117259 | Medicaid | VA | |
| 433215 | Other | VA | ANTHEM BCBS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc - Two Virginias | Bluefield, WV | Dialysis facility |
| Fmc - Mercer County | Princeton, WV | Dialysis facility |
| Fmc - Toledo Laskey Dialysis | Toledo, OH | Dialysis facility |
| Promedica Toledo Hospital | Toledo, OH | Hospital |
| Princeton Community Hospital | Princeton, WV | Hospital |
| South Georgia Medical Center | Valdosta, GA | Hospital |
| Mercy St Vincent Medical Center | Toledo, OH | Hospital |
| Sgmc Lanier Campus | Lakeland, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nephrology And Hypertension | 1557467628 | 3 |
| Toledo Clinic Incorporated | 5698673382 | 248 |
News Archive
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
In light of the findings from the Prostate Testing for Cancer and Treatment trial published yesterday in the New England Journal of Medicine, the American Society for Radiation Oncology would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study.
ADVENTRX Pharmaceuticals, Inc. today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009.
Preterm infant girls who received a high amount of dietary docosahexaenoic acid (DHA; an omega-3 fatty acid) had higher measures of neurodevelopment than preterm girls who received a standard amount of DHA, but this effect was not seen among preterm boys, according to a study in the January 14 issue of JAMA.
Osseon Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex SB (steerable balloon) in select regions of Europe and Asia.
› Verified 6 days ago
| Entity Name | Nephrology And Hypertension |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356471486 PECOS PAC ID: 1557467628 Enrollment ID: O20070507000220 |
News Archive
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
In light of the findings from the Prostate Testing for Cancer and Treatment trial published yesterday in the New England Journal of Medicine, the American Society for Radiation Oncology would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study.
ADVENTRX Pharmaceuticals, Inc. today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009.
Preterm infant girls who received a high amount of dietary docosahexaenoic acid (DHA; an omega-3 fatty acid) had higher measures of neurodevelopment than preterm girls who received a standard amount of DHA, but this effect was not seen among preterm boys, according to a study in the January 14 issue of JAMA.
Osseon Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex SB (steerable balloon) in select regions of Europe and Asia.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohamed Abdul Karim Sekkarie, MD 4235 Secor Rd, Toledo, OH 43623-4231 Ph: (304) 327-1873 | Dr Mohamed Abdul Karim Sekkarie, MD 4235 Secor Rd, Toledo, OH 43623-4231 Ph: (419) 479-5529 |
News Archive
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
In light of the findings from the Prostate Testing for Cancer and Treatment trial published yesterday in the New England Journal of Medicine, the American Society for Radiation Oncology would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study.
ADVENTRX Pharmaceuticals, Inc. today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009.
Preterm infant girls who received a high amount of dietary docosahexaenoic acid (DHA; an omega-3 fatty acid) had higher measures of neurodevelopment than preterm girls who received a standard amount of DHA, but this effect was not seen among preterm boys, according to a study in the January 14 issue of JAMA.
Osseon Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex SB (steerable balloon) in select regions of Europe and Asia.
› Verified 6 days ago
Dr. Mani Khorsand Askari, M.D, FACP Nephrology Medicare: Medicare Enrolled Practice Location: 3000 Arlington Ave Ofc, Toledo, OH 43614 Phone: 419-383-6821 Fax: 419-383-6180 | |
Hoda Shabpiray, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3125 Transverse Dr, Toledo, OH 43614 Phone: 419-383-3627 Fax: 419-383-2021 | |
Theodore J. Ware, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2409 Cherry St, Suite 207, Toledo, OH 43608 Phone: 419-251-4696 Fax: 419-251-3572 | |
Muhammad Rizwan Faisal, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-291-1111 | |
Drew Randall Oostra, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2109 Hughes Dr Ste 450, Toledo, OH 43606 Phone: 419-291-2003 Fax: 419-479-6977 | |
Dr. Caitlyn Marie Hollingshead, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3000 Arlington Ave # Ms 1201, Toledo, OH 43614 Phone: 419-383-3780 Fax: 419-383-2021 | |
Naeem A Lughmani, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4235 Secor Rd, Toledo, OH 43623 Phone: 419-479-5392 |